Treatment of preeclampsia with hydroxychloroquine: a review

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 31, Issue 4, 2018, Pages 525-529

  Abd Rahman, Rahana ^a,c   DeKoninck, Philip ^b   Murthi, Padma ^b   Wallace, Euan M ^b,c  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b MONASH UNIVERSITY   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

antimalarial drugs; mechanisms of action; Preeclampsia

Indexed keywords

HYDROXYCHLOROQUINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; ANTIMALARIAL AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL PROTECTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PRURITUS; REVIEW; VASCULAR PROTECTIVE EFFECT; FEMALE; PREGNANCY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADJUVANTS, PHARMACEUTIC; ANTIMALARIALS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 85040926017     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767058.2017.1289511     Document Type: Review

References (40)

1. Wallace DJ., The history of antimalarials. Lupus 1996;5:S2–3.
2. Page F., Treatment of lupus erythematosus with mepacrine. The Lancet 1951;2:755–8.
3. Miyachi Y, Yoshioka A, Imamura S, et al. Antioxidant action of antimalarials. Ann Rheum Dis 1986;45:244–8.
4. Ziegler H, Unanue E., Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 1982;79:175–8.
5. Cohen S, Yielding K., Spectrophotometric studies of the interaction of chloroquine with deoxyribonucleic acid. J Biol Chem 1965;240:3123–31.
6. Lesiak A, Narbutt J, Sysa-Jedrzejowska A, et al. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 2010;19:683–8.
7. Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011;186:4794–804.
8. Singh A, Chowdhary V., Pregnancy-related issues in women with systemic lupus erythematosus. Int J Rheum Dis 2015;18:172–81.
9. Hung T-H, Burton G. Hypoxia and reoxygenation: a possible mechanism for placental oxidative stress in preeclampsia. Taiwan J Obstet Gynecol 2006;45:189–200.
10. Shen F, Wei J, Snowise S, et al. Trophoblast debris extruded from preeclamptic placentae activates endothelial cells: a mechanism by which the placenta communicates with the maternal endothelium. Placenta 2014;35:839–47.
11. Mandang S, Manuelpillai U, Wallace EM., Oxidative stress increases placental and endothelial cell activin A secretion. J Endocrinol 2007;192:485–93.
12. Gu Y, Lewis DF, Wang Y., Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008;93:260–6.
13. Roberts L, LaMarca BB, Fournier L, et al. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 2006;47:615–18.
14. Murphy SR, LaMarca BB, Cockrell K, et al. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010;55:394–8.
15. LaMarca BB, Cockrell K, Sullivan E, et al. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 2005;46:82–6.
16. Ryan MJ, McLemore GR, Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 2007;292:R736–42.
17. Sun S, Rao N, Venable J, et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007;6:223–35.
18. Sacre K, Criswell LA, McCune JM., Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012;14:R155.
19. Knight M, Redman C, Linton E., Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 1998;105:632–40.
20. Scharfe-Nugent A, Corr SC, Carpenter SB, et al. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol 2012;188:5706–12.
21. Lim R, Acharya R, Delpachitra P, et al. Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am J Obstet Gynecol 2015;212:86.e1–12.
22. Lim R, Adhikari S, Gurusinghe S, et al. Inhibition of activin A signalling in a mouse model of pre-eclampsia. Placenta 2015;36:926–31.
23. Mansour R, Lassoued S, Elgaied A, et al. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010;39:247–53.
24. Gomez-Guzman M, Jimenez R, Romero M, et al. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. Hypertension 2014;64:330–7.
25. Virdis A, Tani C, Duranti E, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Res Ther 2015;17:277.
26. Raijmakers MT, Burton GJ, Jauniaux E, et al. Placental NAD(P)H oxidase mediated superoxide generation in early pregnancy. Placenta 2006;27:158–63.
27. Mohazzab K, Kaminski P, Wolin M., NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994;266:H2568–72.
28. De Keulenaer G, Alexander R, Ushio-Fukai M, et al. Tumour necrosis factor a activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 1998;329:653–7.
29. Ushio-Fukai M, Zafari A, Fukui T, et al. p22phox Is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996;271:23317–21.
30. Sundaresan M, Yu Z-X, Ferrans V, et al. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995;270:296–9.
31. Hobson SR, Acharya R, Lim R, et al. Role of activin A in the pathogenesis of endothelial cell dysfunction in preeclampsia. Pregnancy Hypertens 2016;6:130–3.
32. Selzer F, Sutton-Tyrrell K, Fitzgerald S, et al. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001;37:1075–82.
33. Hart C, Naunton R., The ototoxicity of chloroquine phosphate. Arch Otolaryngol 1964;80:407–12.
34. Suhonen R., Hydroxychloroquine administration in pregnancy. Arch Dermatol 1983;119:185–6.
35. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207–11.
36. Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005;25:86–9.
37. Motta M, Ciardelli L, Marconi M, et al. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am J Perinatol 2007;24:441–7.
38. Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002;46:1121–3.
39. Ostensen M, Brown N, Chiang P, et al. Hydroxychloroquine in human breast milk. Eur J Clin Pharmacol 1985;28:357.
40. American Academy of Pediatrics Committee of Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–89.